Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Ok, so looked into Kurabayashi and MC (or

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
JDUR Member Profile
 
Followed By 11
Posts 660
Boards Moderated 0
Alias Born 06/12/13
160x600 placeholder
Amarin jumps after activist Sarissa discloses stake in 13-F filing Seeking Alpha - 11/16/2021 10:52:48 AM
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021 GlobeNewswire Inc. - 11/16/2021 7:00:00 AM
Amarin Reports Subgroup Data from REDUCE-IT® Highlighting Benefits of VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease (PAD) Presented in Rapid Fire Oral Session Presentation at the American Heart Association Scientific GlobeNewswire Inc. - 11/15/2021 4:30:00 PM
Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire Inc. - 11/11/2021 7:00:00 AM
Latest Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) to be Presented at American Heart Association Scientific Sessions 2021 GlobeNewswire Inc. - 11/8/2021 7:00:00 AM
Amarin shares fall after Q3 topline miss, cash position update Seeking Alpha - 11/3/2021 6:40:19 AM
Amarin EPS beats by $0.01, misses on revenue Seeking Alpha - 11/3/2021 6:03:17 AM
Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 11/3/2021 6:00:00 AM
Amarin Q3 2021 Earnings Preview Seeking Alpha - 11/2/2021 11:36:18 AM
Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021 GlobeNewswire Inc. - 10/20/2021 7:05:00 AM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/12/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:31:42 AM
Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S. GlobeNewswire Inc. - 9/22/2021 9:15:00 AM
Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany GlobeNewswire Inc. - 9/13/2021 7:00:00 AM
Amarin to Participate in September Investment Conferences GlobeNewswire Inc. - 9/13/2021 6:00:00 AM
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology GlobeNewswire Inc. - 8/31/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/30/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/30/2021 7:00:00 AM
Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Societ... GlobeNewswire Inc. - 8/23/2021 3:15:00 AM
CEO Presenting on the Emerging Growth Conference on Tomorrow.  Register Now InvestorsHub NewsWire - 8/17/2021 7:00:00 AM
Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology GlobeNewswire Inc. - 8/16/2021 7:00:00 AM
HLS Therapeutics inks promotional agreement with Pfizer for Vascepa in Canada Seeking Alpha - 8/16/2021 6:55:44 AM
Amarin Q2 Earnings, Revenues Surpass Estimates TipRanks - 8/5/2021 9:58:38 AM
Amarin posts Q2 earnings beat, provides cash position update Seeking Alpha - 8/5/2021 7:58:34 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2021 6:09:55 AM
JDUR   Sunday, 04/05/20 04:39:34 PM
Re: None
Post # of 362229 
Ok, so looked into Kurabayashi and MC (or whoever posted) is 100% correct in the EPA group being not being statistically significant with relationship to the control group in regards to the drop in APO-B. The Judge erroneously cites the P<.001 as being a statistical significant when it is only describing the variance between the measured subjects of the EPA group.

In the study the control group and epa group were independently studied for a possible variance (this P value was calculated using a repeated measures test) and the two groups were compared against each other using a t-test. The t-test produced results that were NOT SIGNIFICANT meaning any person (skilled or not) would assume APO-B was not reduced. Just looking at the data, a -6.9% reduction is already a small value. THEN you take the -1.5% the control group decreased (6.9%-1.5% = 5.4%) and you have an even smaller number. THEN you factor in that the EPA group started with 1.1% higher APO-B level (5.4-1.1=4.3%) and you get an even smaller number.

This is huge for the case as the Judge ruled in favor of two other secondary conditions and an appellate court cannot reject the notion that this interpretation is insignificant in the outcome of the case.

Furthermore, another huge issue is the judge taking the expert opinion that 5% of the time the drug is prescribed <12 weeks as a grounds to promote the "non-infringement" citing case precedent with another ruling of 5% being deemed significant. Knowing the expanded usage being 2-3+ times that (all relating to long term usage), this number would go down to 1.6-2.5%! That means that if AMRN is bringing in 1bil/yr in revenue, then Himka can only (under the grounds/belief of not infringing) expect around 2 million. Why does their press release cite Vascepa's entire sales? Are they planning on infringing or are they misrepresenting a claim in violation with SEC regs?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences